Journal of Nutrition

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nakagawa, K.
Right arrow Articles by Miyazawa, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nakagawa, K.
Right arrow Articles by Miyazawa, T.
© 2007 American Society for Nutrition J. Nutr. 137:1938-1943, August 2007


Nutrition and Disease

In Vivo Angiogenesis Is Suppressed by Unsaturated Vitamin E, Tocotrienol1,2

Kiyotaka Nakagawa3, Akira Shibata3, Shinji Yamashita3, Tsuyoshi Tsuzuki3,4, Jun Kariya5, Shinichi Oikawa6 and Teruo Miyazawa3,*

3 Food and Biodynamic Chemistry Laboratory, Graduate School of Agricultural Science, Tohoku University, Sendai 981-8555, Japan; 4 Department of Food Management, School of Food, Agricultural and Environment Sciences, Miyagi University, Sendai 982-0215, Japan; 5 Project M Co. Ltd., Sendai 980-0014, Japan; and 6 Department of Medicine, Nippon Medical School, Tokyo 113-8603, Japan

* To whom correspondence should be addressed. E-mail: miyazawa{at}biochem.tohoku.ac.jp.

Antiangiogenic therapy using drugs and food components is a recognized strategy for the prevention of various angiogenesis-mediated disorders such as tumor growth, diabetic retinopathy, and rheumatoid arthritis. Our preliminary cell culture studies, using both bovine aortic endothelial cells and human umbilical vein endothelial cells (HUVEC) on screening for food-derived antiangiogenic compounds, showed tocotrienol (T3), an unsaturated version of vitamin E, to be a potential angiogenic inhibitor. We therefore investigaged the in vivo antiangiogenic properties of T3 using 2 well-characterized angiogenic models [mouse dorsal air sac (DAS) assay and the chick embryo chorioallantoic membrane (CAM) assay]. In the DAS assay, the increased neovascularization (angiogenesis index, 4.8 ± 0.6) in tumor cell–implanted mice was suppressed (angiogenesis index, 2.7 ± 0.6) by dietary supplementation of 10 mg T3-rich oil/d (equivalent to 4.4 mg T3/d). In the CAM assay, T3 (500–1000 µg/egg) inhibited new blood vessel formation on the growing CAM and increased the frequency of avascular zone (36–50%). To evaluate the antiangiogenic mechanism, we conducted cell-culture studies and found that T3 significantly reduced fibroblast growth factor -induced proliferation, migration, and tube formation in HUVEC (P < 0.05), with {delta}-T3 having the highest activity. Western blot analysis revealed that {delta}-T3 suppressed the phosphorylation of phosophoinositide-dependent protein kinase (PDK) and Akt, and increased the phosphorylation of apoptosis signal-regulating kinase and p38 in fibroblast growth factor-treated HUVEC, indicating that the antiangiogenic effects of T3 are associated with changes in growth factor-dependent phosphatidylinositol-3 kinase /PDK/Akt signaling as well as induction of apoptosis in endothelial cells. Our findings suggest that T3 has potential as a therapeutic dietary supplement for preventing angiogenic disorders, and therefore future clinical study will be required to evaluate the efficacy and safety of T3.








Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]